The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
First Report of the Emergence of CTX-M-Type Extended-Spectrum β-Lactamases (ESBLs) as the Predominant ESBL Isolated in a U.S. Health Care System
Open accessAbstract
CTX-M-type extended-spectrum β-lactamases (ESBLs) have become increasingly common worldwide, with the notable exception of the United States, where TEM- and SHV-type ESBLs have appeared to predominate. We have noted the emergence of ESBLs in our health care system (the University Health System in San Antonio, TX), especially in Escherichia coli isolates, that preferentially hydrolyze cefotaxime rather than ceftazidime, suggesting the possibility of CTX-M-type enzymes. Microbiology laboratory records were reviewed to identify ESBL-producing isolates and to compare the diameters of ceftazidime disk diffusion zones of inhibition to cefotaxime zone diameters. All isolates had been initially detected and confirmed using the procedures recommended by the Clinical and Laboratory Standards Institute. A total of 94 stored ESBL-producing isolates recovered between January 2000 and June 2006 (predominately from blood and normally sterile fluids) were retrieved for further study and screened using PCR primers specific for the presence of CTX-M, TEM, and SHV ESBLs. Only small numbers of retained ESBL-producing isolates were available for study in 2000 and 2002. The percentages of available ESBL-producing organisms in the following years were found to produce CTX-M enzymes: 2000, 25%; 2001, 10%; 2002, 0%; 2003, 60%; 2004, 69%; 2005, 89%; and 2006, 70%. The most common CTX-M-type ESBL was CTX-M-15, followed by CTX-M-16, CTX-M-8, and CTX-M-14. Comparing the disk diffusion zone diameters of cefotaxime and ceftazidime was helpful with the initial recognition of CTX-M-producing E. coli , which had an average cefotaxime zone diameter 7 mm smaller than the ceftazidime zone. However, comparing ceftazidime and cefotaxime zones for CTX-M-producing Klebsiella spp. was not helpful with initial recognition. CTX-M enzymes were also identified in Proteus mirabilis , Enterobacter spp., and Morganella morganii . Based on pulsed-field gel electrophoresis typing of the E. coli isolates, the CTX-M-producing isolates did not represent the spread of a single clone in the institution or in the community. In conclusion, CTX-M-type ESBLs are now the most common ESBL type isolated from patients in our health care system and may also be present but unrecognized in other U.S. locales.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Growing Group of Extended-Spectrum β-Lactamases: the CTX-M Enzymes
Bonnet, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.1-14.2004 · Cited by 1,494 · cited 5×
“However, in recent years, CTX-M-type ESBLs have emerged as the predominant type of ESBL found in many regions of the world, including South America, Europe, and, more recently, parts of Canada (2, 10, 16, 20).”
BackgroundInfluential
Cited by
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B., Fridkin, S., & National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities (2013) · Infection Control & Hospital Epidemiology · doi:10.1086/668770 · Cited by 1,582
CTX-M Enzymes: Origin and Diffusion
Cantón, R., González-Alba, J. M., & Galán, J. C. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00110 · Cited by 974
Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection
Castanheira, M., Simner, P. J., & Bradford, P. A. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab092 · Cited by 796
Johnson, J. R., Johnston, B., Clabots, C., Kuskowski, M. A., & Castanheira, M. (2010) · Clinical Infectious Diseases · doi:10.1086/653932 · Cited by 510
Ben‐Ami, R., Rodríguez‐Baño, J., Arslan, H., Pitout, J. D. D., Quentin, C., Calbo, E. S., Azap, Ö. K., Arpin, C., Pascual, A., Livermore, D. M., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/604713 · Cited by 462
Peirano, G., & Pitout, J. D. D. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.11.003 · Cited by 443
Pitout, J. D. D. (2010) · Drugs · doi:10.2165/11533040-000000000-00000 · Cited by 376
Extended-spectrum β-lactamase-producing organisms
Falagas, M. E., & Karageorgopoulos, D. E. (2009) · Journal of Hospital Infection · doi:10.1016/j.jhin.2009.02.021 · Cited by 346
Zhang, Y., Zhao, C., Wang, Q., Wang, X., Chen, H., Li, H., Zhang, F., Li, S., Wang, R., & Wang, H. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01127-16 · Cited by 333
The clinical consequences of antimicrobial resistance
Rice, L. B. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.08.001 · Cited by 291
Zhanel, G. G., DeCorby, M., Laing, N., Weshnoweski, B., Vashisht, R., Tailor, F., Nichol, K. A., Wierzbowski, A., Baudry, P. J., Karlowsky, J. A., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01538-07 · Cited by 271
Murphy, C. N., Fowler, R., Balada-Llasat, J. M., Carroll, A., Stone, H., Akerele, O., Buchan, B., Windham, S., Hopp, A., Ronen, S., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00128-20 · Cited by 269
Abdelkader, M. M., Aboshanab, K. M., El-Ashry, M. A., & Aboulwafa, M. M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171349 · Cited by 44
Metadata
- Authors
- Lewis, J. S., Herrera, M., Wickes, B., Patterson, J. E., & Jorgensen, J. H.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-11
- Volume
- 51
- Issue
- 11
- Pages
- 4015-4021
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2138505176
- Cited by
- 231
- References
- 1
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.